European Journal of Nuclear Medicine and Molecular Imaging

Papers
(The H4-Index of European Journal of Nuclear Medicine and Molecular Imaging is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer336
18F-FDG brain PET hypometabolism in patients with long COVID257
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET180
Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings144
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres139
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0127
Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT123
18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?119
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer113
Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers113
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients109
The EANM practice guidelines for parathyroid imaging109
Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study99
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-61798
Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT95
Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study95
The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study94
Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation91
Histologic subtype classification of non-small cell lung cancer using PET/CT images91
68Ga-FAPI-PET/CT in patients with various gynecological malignancies88
Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives87
Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers85
Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study84
PET/MRI in prostate cancer: a systematic review and meta-analysis83
Automated detection and quantification of COVID-19 pneumonia: CT imaging analysis by a deep learning-based software83
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers82
Cellular sources of TSPO expression in healthy and diseased brain82
Deep learning-assisted ultra-fast/low-dose whole-body PET/CT imaging81
Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer79
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 377
Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants76
A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy76
State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis75
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study74
Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT74
Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules73
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model72
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)71
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds71
Deep-JASC: joint attenuation and scatter correction in whole-body 18F-FDG PET using a deep residual network71
Deep learning-based attenuation map generation for myocardial perfusion SPECT70
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis70
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI70
The image quality, lesion detectability, and acquisition time of 18F-FDG total-body PET/CT in oncological patients69
COVID-19 pandemic: guidance for nuclear medicine departments69
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands68
The potential added value of FDG PET/CT for COVID-19 pneumonia67
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.66
EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging65
Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer64
Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imagin63
Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging62
A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study61
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging61
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy61
18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma61
Decoding COVID-19 pneumonia: comparison of deep learning and radiomics CT image signatures60
End-to-end automatic differentiation of the coronavirus disease 2019 (COVID-19) from viral pneumonia based on chest CT60
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports60
Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma59
The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis59
0.055066823959351